10
Feb

PCa agent detects 97% of lesions when paired with PET

In a small study of men with prostate cancer, researchers found a novel agent combined with positron emission tomography (PET) imaging detected 97% of cancerous lesions. The new modality holds promise but will require validation in a larger cohort of patients in one or more separate institutions, one thought leader told Urology Times. The modality, …

9
Feb

Big Ideas in Cancer: A Philadelphia Public Education Event

The event, entitled “Cancer Precision Medicine: Big Ideas in Research, Treatment, and Prevention,” featured six Pennsylvania cancer center directors on a stage together for the first time: AACR President-Elect Nancy Davidson, MD, director of the University of Pittsburgh Cancer Institute, joined Dario Altieri, MD, CEO and director of the Wistar Institute Cancer Center; Chi Dang, …

4
Feb

“Hormone Holiday” Can Improve QoL for Select Patients With Prostate Cancer

   Androgen-deprivation therapy, while an effective treatment for prostate cancer, can result in side effects and a reduced quality of life. Allowing low-risk patients to take breaks between treatments—a practice known as intermittent hormonal therapy, or a “hormone holiday”—may combat these challenges without impacting survival. A recent systematic review and meta-analysis conducted by JAMA Oncology …

3
Feb

Prostate Cancer Lesions Accurately Detected by New Imaging Agent

Thomas Jefferson University researchers recently tested a new imaging technique to detect prostate cancer cells and malignant lesions — a technique they also developed — and report that it is both highly accurate and more effective than current detection methods. Their article, “VPAC1 Targeted 64Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man,” was published in Urology. …

28
Jan

NCI-designated Cancer Centers Urge HPV Vaccination for the Prevention of Cancer

Approximately 79 million people in the United States are currently infected with a human papillomavirus (HPV) according to the Centers for Disease Control and Prevention (CDC), and 14 million new infections occur each year. Several types of high-risk HPV are responsible for the vast majority of cervical, anal, oropharyngeal (middle throat) and other genital cancers. …

25
Jan

Jefferson Liver Tumor Center Video Blog: Dr. Cataldo Doria

The Jefferson Liver Tumor Center is a multidisciplinary collaboration of hepatologists, interventional and imaging radiologists, surgeons, medical and radiation oncologists, anesthesiologists, nurse practitioners, social workers, transplant coordinators, and specialists in integrative medicine. Dr. Cataldo Doria, the Center’s surgical director, shares some information on its services, and how it helps patients with liver diseases and liver …

21
Jan

TJU Researchers Find Link Between Obesity and Increased Risk of Colorectal Cancer

Thomas Jefferson University scientists say the culprit is excess calories, but risk can be reversed through lifestyle modification or, potentially, use of an approved drug. Obesity has long been associated with increased risk of colorectal cancer, but the link has never been understood.Now, a research team led by investigators at Thomas Jefferson University has revealed the …

19
Jan

Dr. Kelly featured in the Inquirer regarding Moonshot Announcement

Vice President Biden met with scientists at the University of Pennsylvania’s Abramson Cancer Center Friday afternoon, officially launching his “moonshot” quest to cure cancer. “We’re on the cusp of phenomenal breakthroughs,” Biden said, adding that President Obama would be issuing an executive order that would get every federal agency involved in the effort. “There are …

14
Jan

Three Hits to Fight Lung Cancer

In experimental models of lung cancer, researchers show that a combo of two drugs plus radiation could make a subset of treatment-resistant lung cancers susceptible to therapy. (PHILADELPHA) – Although the most common type of lung cancer – non-small cell lung cancer (NSCLC) – has recently seen major treatment advances in some genetic subtypes, other …

12
Jan

SKCC Member receives R21 Grant

Dr Isidore Rigoutsos, PhD Director of Computational Medicine Center: Cancer Biology, Pathology, Anatomy and Cell Biology for the Sidney Kimmel Cancer Center and Professor Biochemistry & Molecular Biology was recently awarded an R21 grant for the Discovery of Novel miRNAs and isomiRs and Use in Sub-typing TCGA cancers.  Summary Statement from Dr. Rigoutsos: Recently, we …

11
Jan

Atezolizumab Could Change Standard of Care in Metastatic Urothelial Cancers

“This primary analysis of IMvigor 210 demonstrated that atezolizumab has the potential to change the standard of care for metastatic urothelial cancers.” – Jean H. Hoffman-Censits, MD Second-line treatment with atezolizumab (MPDL3280A) resulted in a median overall survival (OS) of 11.4 months in patients with locally advanced or metastatic urothelial carcinoma (mUC) and who showcased …

8
Jan

SKCC Researcher Named one of 3 New Outrun the Sun Melanoma Research Scholars

  OUTRUN THE SUN NAMES THREE NEW MELANOMA RESEARCH SCHOLARS Jessica Teh, Post Doc Fellow – Dr. Andrew Aplin Lab Indianapolis: Outrun the Sun, Inc., (www.outrunthesun.org) a nonprofit organization supporting skin cancer education and melanoma research, welcomes three new melanoma researchers to the Outrun the Sun Melanoma Research Scholar Program. The 2015 Scholars are: Brian …

Page 1 of 19